Low-dose Versus Standard-dose Remimazolam for Prevention of Emergence Agitation After Nasal Surgery
Key facts
- Who runs it
- Jeju National University School of Medicine
- Where
- South Korea1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 138 people, planned
- Started
- 24 Jul 2026
- Expected to end
- 31 Jul 2027
- Type of study
- Interventional, 2 groups
- Treatments tested
- Remimazolam
- Record updated
- 31 July 2026
Who can take part
- Age
- 18 years to 79 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Adults aged 18 to 79 years
- Scheduled to undergo elective nasal surgery under sevoflurane-based general anesthesia at Jeju National University Hospital
- Able to provide written informed consent
Who cannot take part
- History of allergy or hypersensitivity to benzodiazepines
- Inability to provide informed consent due to cognitive impairment
- Preexisting psychiatric disorders
- History of alcohol or substance abuse
- Contraindications to remimazolam
- Inability to assess the Riker Sedation-Agitation Scale (SAS)
- Body mass index (BMI) > 40 kg/m²
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 79 years old?
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Emergence agitation (EA) is a common complication during recovery from sevoflurane anesthesia, particularly after nasal surgery. Although remimazolam 0.1 mg/kg has been shown to reduce the incidence of EA, this dose may produce excessive sedation and increase the risk of intraoperative burst suppression.
Read full original descriptionShow less
This randomized, double-blind, non-inferiority trial will compare low-dose remimazolam (0.03 mg/kg) with the standard dose (0.1 mg/kg) administered at the end of surgery in adult patients undergoing nasal surgery under sevoflurane anesthesia. The primary objective is to determine whether low-dose remimazolam is non-inferior to the standard dose in preventing emergence agitation. Secondary outcomes include burst suppression, recovery profiles, and safety outcomes.
The 2 groups in the trial
- Standard-dose RemimazolamTreatment being tested
Participants will receive remimazolam 0.1 mg/kg intravenously immediately after discontinuation of sevoflurane at the end of nasal surgery under general anesthesia.
Treatment: Remimazolam
- Low-dose RemimazolamTreatment being tested
Participants will receive remimazolam 0.03 mg/kg intravenously immediately after discontinuation of sevoflurane at the end of nasal surgery under general anesthesia.
Treatment: Remimazolam
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Low-dose Versus Standard-dose Remimazolam for Prevention of Emergence Agitation After Nasal Surgery Under Sevoflurane Anesthesia: A Randomized Double-blind Non-inferiority Trial
- Criteria questions
- Built from NCT07740655, who can take part
- Record updated
- 31 July 2026